Does one-time ashwagandha intake improve cognitive function?

Submission date 31/10/2021	Recruitment status No longer recruiting	 Prospectively registered Protocol
Registration date 02/11/2021	Overall study status Completed	 [_] Statistical analysis plan [X] Results
Last Edited 03/01/2023	Condition category Other	 Individual participant data

Plain English summary of protocol

Background and study arms

Ashwagandha (ASH) has long been used in the traditional Ayurvedic system of medicine to enhance memory and improve cognition. Human intervention studies have linked Ashwagandha to increased cognition in patients with early dementia or bipolar disorder, but studies in healthy populations are limited. It is currently unknown if one-time supplementation with Ashwagandha can improve cognitive performance in young healthy adults. The aim of this study is to examine the effect of acute ingestion of 400 mg of ashwagandha on executive function including general attention, sustained attention, attentional shifting, and/or working memory in young adults.

Who can participate? Healthy men and women between the ages of 18 to 59 years

What does the study involve?

Participants will be randomly allocated to receive ASH or placebo (dummy) capsules, and then perform four cognitive function tests that assess a range of cognitive and executive function aspects.

What are the possible benefits and risks of participating? The potential benefit of participating is an increase in executive functioning.

Where is the study run from? Texas A&M University (USA)

When is the study starting and how long is it expected to run for? April 2019 to November 2019.

Who is funding the study? Specnova Inc. (USA)

Who is the main contact? Dr Richard B. Kreider rbkreider@tamu.edu

Contact information

Type(s) Scientific

Contact name Prof Richard Kreider

ORCID ID http://orcid.org/0000-0002-3906-1658

Contact details Texas A&M University 675 Kimbrough Blvd. Building #1542 College Station, TX United States of America 77843-4253 +1 (0)979 458 1498 rbkreider@tamu.edu

Additional identifiers

EudraCT/CTIS number Nil known

IRAS number

ClinicalTrials.gov number Nil known

Secondary identifying numbers AcuteAshwagandha2019

Study information

Scientific Title The effect of acute ashwagandha supplementation on cognitive function

Study objectives Acute ashwagandha extract improves cognition.

Ethics approval required Old ethics approval format

Ethics approval(s)

Approved 19/07/2019, Texas A&M University Institutional Review Board (517 Blocker Building, 155 Ireland Street, Texas A&M University, College Station, TX 778431, USA; +1 (0)979 458 4067; irb@tamu.edu), ref: IRB2019-0453D

Study design Interventional double-blinded randomized crossover controlled trial

Primary study design Interventional

Secondary study design Randomised cross over trial

Study setting(s) Other

Study type(s) Other

Participant information sheet No participant information sheet available

Health condition(s) or problem(s) studied

Improving cognition in healthy individuals

Interventions

Subjects consumed capsules containing 400 mg of a proprietary root and leaves extract of ashwagandha (NooGandha®, Specnova, Boca Raton, FL, USA) or capsules containing 400 mg of a wheat flour placebo (Placebo) once they have completed baseline testing with 8 ounces of water. A computer generated randomization to treatment was used. Once subjects were randomized to start, they followed the counter balance progression.

Intervention Type

Supplement

Primary outcome measure

The Psychology Experiment Building Language (PEBL) software program (Version 2.1, http://pebl.sourceforge.net) was used to administer four cognitive function tests that assessed a range of cognitive and executive function aspects:

1. Berg-Wisconsin Card Sorting Task test (BCST) at baseline, 1, 2, 3, 4, 5 and 6 hours after ingestion

2. The Go/No-Go test (GNG) at baseline, 1, 2, 3, 4, 5 and 6 hours after ingestion

3. Sternberg Task Test (STT) at baseline, 1, 2, 3, 4, 5 and 6 hours after ingestion

4. Psychomotor Vigilance Task Test (PVTT) at baseline, 1, 2, 3, 4, 5 and 6 hours after ingestion

Secondary outcome measures

There are no secondary outcome measures

Overall study start date

01/04/2019

Completion date 10/11/2019

Eligibility

Key inclusion criteria

Apparently healthy males and females between the ages of 18 to 59 years were recruited to participate in the study.

All subjects were healthy and free from known:

- 1. Cognitive deficit conditions
- 2. Wheat flour allergies
- 3. Sleep disorders
- 4. Cardiovascular, metabolic, or pulmonary diseases
- 5. History of hypertension, migraine headaches, cardiac arrhythmias, or anxiety
- 6. Gastrointestinal reflux disease or ulcers

Participant type(s)

Healthy volunteer

Age group

Adult

Lower age limit

18 Years

Upper age limit

59 Years

Sex

Both

Target number of participants 15

Total final enrolment

Key exclusion criteria

Subjects who were taking prescription medications in the month prior to the initiation of the study and/or were told by a physician to abstain or restrict caffeine and/or stimulant intake

Date of first enrolment 20/07/2019

Date of final enrolment 10/11/2019

Locations

Countries of recruitment United States of America Study participating centre Texas A&M University 675 Kimbrough Blvd Building #1542 College Station, Texas United States of America 77843-4253

Sponsor information

Organisation Specnova Inc.

Sponsor details 8609 Westwood Center Drive #110

Tysons Corner, VA United States of America 22182 +1 (0)720 245 4096 sebastian@specnova.com

Sponsor type Industry

Website https://www.specnova.com

Funder(s)

Funder type Industry

Funder Name Specnova Inc.

Results and Publications

Publication and dissemination plan

Planned publication in peer-reviewed scientific journal.

Intention to publish date

31/12/2021

Individual participant data (IPD) sharing plan

All data generated or analyzed during this study will be included in the subsequent results publication.

IPD sharing plan summary

Published as a supplement to the results publication

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article		20/09/2022	03/01/2023	Yes	No